North America Isoxazoline Drugs Market Size, Share & Trends Analysis Report By Product Type (Fluralaner, Sarolaner, Lotilaner, Afoxolaner), By Pet Type (Dogs, Cats) and By Country (US, Canada) Forecasts, 2026-2034

North America Isoxazoline Drugs Market Overview

The North America isoxazoline drugs market size was valued at USD 1.93 billion in 2025 and is projected to grow from USD 2.11 billion in 2026 to USD 4.32 billion by 2034 at a CAGR of 9.48% during the forecast period, 2026-2034.

Isoxazoline is a relatively new chemical family of five-membered heterocyclic chemical compounds with one oxygen and one nitrogen atom next to each other. Isoxazoline compounds such as fluralaner, afoxolaner, sarolaner, and lotilaner are active components in tick repellents.

Ticks are non-flying insects that are parasites on dogs, cats, and other animals. The host must come into direct contact with a tick in order to become a parasite. Ticks are dangerous to pets because they transmit illnesses such as Lyme disease, Rocky Mountain spotted fever, ehrlichiosis, tularaemia, and STARI (Southern tick-associated rash illness). In order for illnesses to be transferred, a tick must remain attached to a host for several hours. To prevent pets from tick bites, a variety of repellents, insecticides, and growth inhibitors are commercially available.

The isoxazoline class of medicines are oral insecticides that have been approved for the treatment of ectoparasites in companion animals such as dogs and cats. These medications were initially introduced in 2013 as veterinary treatments for ticks and fleas in dogs. Several studies, however, have demonstrated their effectiveness against various veterinary and agricultural parasites. Bravecto, Credlio, Nexgard, and Simparica are examples of FDA-approved isoxazoline medications.

The US FDA has authorised these medications for tick and flea infestation. Some are also licenced for the treatment of gastrointestinal parasite infections and ear mite management. These medications are either consumed or given topically. The majority of active substances were first launched for crop protection and thereafter for companion animals.

Innovations on current medications for new indications in oral and topical formulations, as well as increased awareness of ectoparasite prevention and control of fleas and ticks, are expected to drive market expansion. The market is divided into three sections: product type, pet kind, and geography.

North America: 5,603million USD (2030 value); CAGR: 18.1%

Segmental Analysis

By Product Type

The North America isoxazoline drugs market is segmented into Fluralaner, Sarolaner, Lotilaner, and Afoxolaner. These active ingredients are used in veterinary antiparasitic products for controlling fleas, ticks, and certain mite infestations in companion animals. Their availability in oral and topical formulations supports different treatment and prevention requirements across the region.

Fluralaner, Sarolaner, Lotilaner, and Afoxolaner differ in their approved species, formulations, parasite coverage, and treatment intervals. Growing awareness of preventive pet healthcare and the established availability of these products through veterinary channels are supporting demand for isoxazoline-based treatments in North America.

Request Customizationto receive a tailored report.

By Pet Type

The market is segmented into Dogs and Cats. Dogs represent a major application area, with isoxazoline products widely used for flea and tick control and, depending on the active ingredient, management of certain mite-related conditions. Regular preventive veterinary care and growing attention to parasite control support demand among dog owners.

Cats are another important application segment, with products available in oral and topical formulations depending on the active ingredient and regional approval. Increasing awareness of feline parasite prevention and expanding access to veterinary care are supporting the use of isoxazoline-based products for cats across North America.

Speak to an Analystto discuss market opportunities.

Regional Analysis

In 2021, the Americas will have the highest share of the isoxazoline medicines market, with a CAGR of 18.16 percent during the projected period. One of the primary reasons driving the market's growth is the rising number of medication approvals and greater adoption rate.

List of Key and Emerging Players in North America Isoxazoline Drugs Market